Actively Recruiting
Evaluation of DT-101 Compared to Placebo as Adjunctive Treatment for Adults With Major Depressive Disorder on Medication
Led by Draig Therapeutics Ltd · Updated on 2026-08-12
118
Participants Needed
22
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating a drug called DT-101 for adults with Major Depressive Disorder MDD, a form of depression. This study aims to learn if DT-101 can help treat depression when added to existing medication. The trial compares DT-101 against a placebo, which looks like the drug but contains no active medicine. Participants who qualify will be randomly assigned to receive either DT-101 or placebo for 8 weeks. During this time, they will continue their usual depression medication. The study includes physical and neurological exams, blood and urine tests, and clinical assessments to monitor safety and how the body processes DT-101. Participants will visit the clinic regularly for health checks and to complete questionnaires about their depression symptoms. Researchers will measure changes in depression severity using specific rating scales over 56 days. The study also collects data to analyze how well participants tolerate the drug and its effects on their condition.
CONDITIONS
Brief Title
A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
Research Team
A
Aeron-1 Clinical Team
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
